trending Market Intelligence /marketintelligence/en/news-insights/trending/kyuoQkCBRgyFJ07CkzG48A2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Acorda Therapeutics to reduce staff by 25% to focus on Parkinson's therapy

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

The Market Intelligence Platform


Acorda Therapeutics to reduce staff by 25% to focus on Parkinson's therapy

Acorda Therapeutics Inc. is reducing its workforce by 25% in a restructuring to focus its resources on the launch of its Parkinson's disease treatment Inbrija.

The Ardsley, N.Y.-based drugmaker said it expects the workforce reduction to be completed in the first quarter of 2020.

Inbrija is a formulation of levodopa, one of the main drugs used to treat certain symptoms of Parkinson's disease. The therapy is used for patients experiencing so-called off periods when the effects of an existing medication start to wear off in between doses or the symptoms of Parkinson's reemerge.

The drug is approved by the U.S. Food and Drug Administration and the European Commission.